Bioprocess Analyzers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Bioprocess Analyzers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

The Bioprocess Analyzers Market size is estimated at USD 2 billion in 2024, and is expected to reach USD 4.17 billion by 2029, growing at a CAGR of 15.80% during the forecast period (2024-2029).

The pandemic had an effect on the market studied. Factors such as high titer, constant product quality, the robustness of the process, fast turnaround times, and scalability are some of the reasons why bioprocess containers are being used in vaccine production. There are many companies whose products are being used for COVID-19 vaccine research. With the large-scale vaccination programs around the world and the new investments in the biopharmaceutical industry, the market studied is expected to regain its potential over the years.

The major factors attributed to the growth of the market are the growing interest in the development of advanced medicines and vaccines and the increasing demand for biologics. These factors are expected to increase the market's growth. The rising geriatric population is susceptible to chronic diseases, which is increasing the demand for biologics. Cardiovascular disease is one of the leading causes of death globally, in which myocardial infarction (MI) is a major event. According to the article published in March 2021 by the National Library of Medicine, current therapies do not adequately address the multiple dysregulated systems following MI. The research to develop drug delivery systems for biologics is expected to increase over the forecast period, positively impacting the growth of the market. The increasing investments by the major market players in the development of biologics are driving the market's growth. In 2022, Aurobindo Pharma (CuraTeQ Biologics) planned to invest around INR 300 crore in capacity expansion of biologics manufacturing facilities, and this facility is likely to be fully operational by 2026. Furthermore, biologics is efficient in treating rheumatoid arthritis and Crohn's disease, which may lead to the growth of bioprocess analyzers in the production process of biological products. Thus, the aforementioned factors are expected to increase the market's growth during the forecast period.

However, difficulties faced during the upstream and downstream process due to the small-sized bioprocessing equipment and the relatively high cost of the raw materials are constraints to the growth of the market.

Bioprocess Analyzers Market Trends

Recombinant Protein Segment is Expected to Hold a Significant Market Share over the Forecast Period

A recombinant protein is encoded by recombinant DNA that involves the insertion of DNA encoding that protein into bacterial or mammalian cells. The protein is then purified after getting expressed in these cells. Recombinant protein is produced either by molecular cloning or through polymerase chain reaction (PCR). The major factors fueling the market's growth are the implementation of strategic initiatives by the market players, such as collaborations, approvals, and growing research and development activities. In March 2022, Pfizer Inc. and OPKO Health Inc. reported that the USFDA issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for somatrogon. Somatrogon is an investigational once-weekly long-acting recombinant human growth hormone for the treatment of growth hormone deficiency (GHD) in pediatric patients. For instance, in November 2021, I-Mab entered into a strategic collaboration agreement with Jumpcan Pharmaceutical Group, a leading Chinese pharmaceutical company specializing in and committed to pediatric medicines, for the development, manufacturing, and commercialization of I-Mab's highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa (TJ101), in mainland China. Similarly, in April 2022, Algenex received the final audit report from AEMPS, confirming that Algenex complies with the principles of the GMP for active substances of the European Union. This certification provides validation of Algenex's CrisBio technology platform for the production of recombinant proteins within the quality standards of the European pharmaceutical industry. CrisBio is Algenex's proprietary and patent-protected Baculovirus vector-mediated expression platform that harnesses the power of insects to act as natural single-use bioreactors by-product protein in chrysalises. CrisBio represents a new paradigm in biologics production, offering a quick, linearly scalable solution to meet the global demand for recombinant protein production without significant CAPEX investment.

Thus, the aforementioned factors are expected to increase the market's growth.

North America is Expected to have a Significant Share in the Market over the Forecast Period

North America is expected to have a significant share in the bioprocess analyzers market throughout the forecast period. Rising acquisitions between contract research organizations in the United States are expected to drive the market in this region. For instance, in March 2021, the United States HHS collaborated with Merck to repurpose its existing Merck facilities for rapid large-scale manufacturing of vaccines and therapeutics for use in public health emergencies, including the COVID-19 pandemic. Thus, the steps taken by the government to increase the production of vaccines in the country will boost the demand for bioprocess bags, as they are majorly used for vaccine production, thereby driving the market. Thus, such investments and partnerships by key players to boost the production of vaccines in the country indicate the growing demand for vaccines. To tackle this demand, the production of bioprocess containers is also expected to increase, thus driving the market. The establishment of manufacturing facilities, partnerships, and acquisitions indicating the boost in the manufacturing of 2D manufacturing bags will also contribute to the market's growth. In June 2021, Entegris Inc., a supplier of advanced materials and process systems for the semiconductor and other high-technology industries, expanded its Life Sciences manufacturing facilities located in the United States by investing USD 30 million. Through this investment, the company is planning to increase the production of the Aramus 2D bag product line and other clean, scalable, and reliable bioprocessing systems.

Thus, the aforementioned factors are expected to increase the market's growth.

Bioprocess Analyzers Industry Overview

The bioprocess analyzers market is moderately competitive and consists of several major players. Some of the companies that are currently dominating the market are F. Hoffmann-La Roche AG, Nova Biomedical Corporation, YSI Inc., Randox Laboratories Ltd, Sartorious AG, Thermo Fisher Scientific, Agilent Technologies, and Kaiser Optical Systems Inc., among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support